Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

70.67
-10.0000-12.40%
Post-market: 71.821.15+1.63%19:56 EDT
Volume:4.37M
Turnover:321.71M
Market Cap:9.95B
PE:-30.94
High:83.55
Open:82.89
Low:70.61
Close:80.67
52wk High:95.49
52wk Low:28.12
Shares:140.86M
Float Shares:122.00M
Volume Ratio:2.45
T/O Rate:3.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:21.38
PE(LYR):-5,795.95

Loading ...

Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 8.93% on Sep 15: What Investors Need To Know

TradingKey
·
10 hours ago

Movement Alert|Arrowhead Pharmaceuticals Falls 8.95% in Regular Trading, Interim Data for Dual-Function RNAi Therapy Triggers Sell-Off

Market Focus
·
10 hours ago

Arrowhead announces interim topline data from Phase 1/2a trial of ARO-DIMER-PA

TIPRANKS
·
Yesterday

Arrowhead Pharmaceuticals - Single Dose Escalation Completed Through 400 Mg; no Drug-Related Saes Reported

THOMSON REUTERS
·
Yesterday

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional Rnai Therapeutic for the Treatment of Mixed Hyperlipidemia

THOMSON REUTERS
·
Yesterday

Arrowhead Pharmaceuticals - Mean Maximal Non-Hdl Cholesterol Reduction of 61% with Single Dose

THOMSON REUTERS
·
Yesterday

Citi adds ‘upside 30-day catalyst watch’ on Arrowhead

TIPRANKS
·
Sep 09

Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target

MT Newswires Live
·
Sep 08

Arrowhead Pharmaceuticals : Citigroup Initiates Coverage with Buy Rating; Target Price $108

THOMSON REUTERS
·
Sep 08

U.S. Research Roundup-Fedex Freight Holding Company, PDF Solutions, Robinhood Markets

Reuters
·
Sep 08

This Biotech Wins a Big FDA Approval. Why Wall Street is Shrugging.

Dow Jones
·
Sep 05

Arrowhead Pharma to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 03

Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says

MT Newswires Live
·
Aug 31

Arrowhead Pharmaceuticals Price Target Maintained with a $100.00/Share by RBC Capital

Dow Jones
·
Aug 31

Arrowhead Pharmaceuticals Posts ESC 2026 Investor Presentation on Shasta-3 and Shasta-4 Results

Reuters
·
Aug 31

Sector Update: Healthcare

MT Newswires Live
·
Aug 31

Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia

MT Newswires Live
·
Aug 31

Arrowhead Phase 3 SHASTA-3, SHASTA-4 studies met primary endpoints

TIPRANKS
·
Aug 31

Arrowhead Pharmaceuticals - Plozasiran Demonstrated Favorable Safety and Tolerability Profile in Phase 3 Studies

THOMSON REUTERS
·
Aug 30

Arrowhead Pharmaceuticals - to File Supplemental Nda with U.S. FDA by Year-End 2026 Using Priority Review Voucher

THOMSON REUTERS
·
Aug 30